Physician profile
Suruchi Kaul
NPI 1962683847
$2,196.99
in general payments reported to CMS, 2019-2025
33 companies · $726 in 2025
The $726 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.23 · 2022: $227 · 2023: $548 · 2024: $655 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,929.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $313.83 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $215.00 | 2023-2025 | Farxiga, Lokelma |
| Lilly USA, LLC | $161.64 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $144.87 | 2023-2025 | |
| Novo Nordisk INC | $136.06 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $118.29 | 2023-2025 | |
| Shield Therapeutics INC | $113.86 | 2023-2025 | Accrufer |
| Novartis Pharmaceuticals Corporation | $90.29 | 2024-2025 | |
| Amgen INC. | $85.01 | 2023-2025 | Repatha, Repatha, Otezla |
| Lundbeck LLC | $64.67 | 2024-2025 | Rexulti |
| Medtronic, INC. | $59.03 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Astellas Pharma US INC | $52.86 | 2023-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $52.30 | 2023-2024 | Xarelto |
| Grt US Holding, INC. | $49.49 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.78 | 2023-2024 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $42.90 | 2022-2024 | |
| Viatris Specialty LLC | $36.89 | 2025 | Yupelri |
| Abbott Laboratories | $34.64 | 2021-2023 | Freestyle Libre 2 |
| Sumitomo Pharma America, INC. | $34.15 | 2023 | Gemtesa |
| Glaxosmithkline, LLC. | $32.61 | 2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.78 | 2024 | Jardiance |
| Ars Pharmaceuticals Operations, INC. | $29.32 | 2025 | Neffy |
| Amarin Pharma, INC. | $28.11 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $27.75 | 2025 | Rexulti |
| Exact Sciences Corporation | $26.38 | 2025 | Cologuard Collection Kit |
| Verona Pharma, INC. | $26.30 | 2025 | Ohtuvayre |
| Eisai INC. | $24.99 | 2025 | |
| Paratek Pharmaceuticals, INC. | $21.69 | 2025 | Nuzyra |
| Amryt Pharma Holdings LTD | $21.00 | 2023 | Mycapssa |
| Merck Sharp & Dohme LLC | $20.54 | 2025 | Lagevrio |
| Scpharmaceuticals INC. | $20.42 | 2025 | |
| Edwards Lifesciences Corporation | $16.95 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suruchi Kaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.